Hedera Dx

Hedera Dx is a Swiss techbio company founded in 2021 in Lausanne. The company aims to make liquid biopsies a standard practice in clinical settings, enhancing therapy options for cancer patients through minimally invasive blood tests. Hedera Dx develops decentralized liquid biopsy solutions that allow hospital laboratories to conduct advanced molecular diagnostics in-house, supporting the needs of decentralized health systems across Europe.

The company offers a comprehensive liquid biopsy solution that includes the Hedera Profiling 2 ctDNA test panel, which detects various cancer biomarkers from blood plasma, and the Hedera Prime platform, a certified software that analyzes sequencing data to provide actionable therapy recommendations. Their end-to-end process involves blood collection, DNA extraction, and data analysis, culminating in physician-reviewed reports for tumor profiling and treatment monitoring. Hedera Dx primarily serves hospital laboratories and oncologists, facilitating streamlined tumor profiling and biomarker-guided therapy selection for cancer patients.